Autologous cell therapy refers to the injection or delivery of human tissue or cells to the same person to treat pathological conditions. For the same purpose, the stem cells are taken out of the patient, harvested, cultured, and transplanted again to the same person. The purpose of this method is to reduce the chance of rejecting treatment in the body. In addition, autologous cell therapy does not require immunosuppression.
This report contains market size and forecasts of Autologous Cell Therapy in Global, including the following market information:
Global Autologous Cell Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Autologous Cell Therapy market was valued at 7441.3 million in 2021 and is projected to reach US$ 16310 million by 2028, at a CAGR of 11.9% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Bone Marrow Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Autologous Cell Therapy include BioTime, Pharmicell, BrainStorm Cell Therapeutics, Opexa Therapeutics, Vericel Corporation and Regeneus, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Autologous Cell Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Autologous Cell Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Autologous Cell Therapy Market Segment Percentages, by Type, 2021 (%)
Bone Marrow
Epidermis
Global Autologous Cell Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Autologous Cell Therapy Market Segment Percentages, by Application, 2021 (%)
Neurology
Orthopedics
Cancer
Wound Healing
Other
Global Autologous Cell Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Autologous Cell Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Autologous Cell Therapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Autologous Cell Therapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
BioTime
Pharmicell
BrainStorm Cell Therapeutics
Opexa Therapeutics
Vericel Corporation
Regeneus